We are live on ! Find out more
TMCI icon

Treace Medical Concepts

127 hedge funds and large institutions have $264M invested in Treace Medical Concepts in 2024 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 55 increasing their positions, 25 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 25

5% less call options, than puts

Call options by funds: $2.93M | Put options by funds: $3.09M

10% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 41

2.83% less ownership

Funds ownership: 66.86%64.03% (-2.8%)

4% less funds holding

Funds holding: 132127 (-5)

51% less capital invested

Capital invested by funds: $538M → $264M (-$274M)

Holders
127
Holders Change
-5
Holders Change %
-3.79%
% of All Funds
1.83%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
37
Increased
55
Reduced
25
Closed
41
Calls
$2.93M
Puts
$3.09M
Net Calls
-$155K
Net Calls Change
-$2.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Wealth Enhancement Advisory Services
26
Wealth Enhancement Advisory Services
Minnesota
$1.6M +$767 +95 +0%
UOC
27
UBS O'Connor
Illinois
$1.42M +$623K +77,063 +57%
Renaissance Technologies
28
Renaissance Technologies
New York
$1.37M +$235K +29,100 +16%
GCP
29
GSA Capital Partners
United Kingdom
$1.27M +$987K +122,154 +176%
N
30
Nuveen
North Carolina
$1.16M -$558K -69,116 -28%
JF
31
Jump Financial
Illinois
$1.13M +$1.01M +124,800 +281%
LIP
32
Lighthouse Investment Partners
Florida
$1.11M +$1.35M +167,500 New
AG
33
Algert Global
California
$1.08M +$842K +104,236 +179%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.07M +$151K +18,721 +13%
Stifel Financial
35
Stifel Financial
Missouri
$1.01M +$597K +73,943 +95%
Bank of America
36
Bank of America
North Carolina
$983K +$284K +35,182 +31%
UBS AM
37
UBS AM
Illinois
$884K +$784K +96,992 +270%
GF
38
Gabelli Funds
New York
$848K -$128K -15,859 -11%
Two Sigma Investments
39
Two Sigma Investments
New York
$838K +$473K +58,551 +87%
Squarepoint
40
Squarepoint
New York
$785K +$716K +88,577 +301%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$783K +$791K +97,895 +495%
DSCM
42
Divisadero Street Capital Management
Florida
$761K
Group One Trading
43
Group One Trading
Illinois
$686K -$153K -18,968 -16%
YIH
44
Y-Intercept (HK)
Hong Kong
$641K +$364K +45,091 +88%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$617K +$253K +31,281 +51%
Swiss National Bank
46
Swiss National Bank
Switzerland
$604K
Jane Street
47
Jane Street
New York
$540K +$405K +50,181 +161%
BFG
48
Bleakley Financial Group
New Jersey
$538K +$654K +80,936 New
SW
49
Simplicity Wealth
New Jersey
$538K +$653K +80,861 New
Verition Fund Management
50
Verition Fund Management
Connecticut
$531K +$430K +53,200 +199%

TMCI Hedge Fund Activity: Q2 2024 in Review

127 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Treace Medical Concepts (TMCI) for Q2 2024, worth a combined $264M — down 51% from $538M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of TMCI and 37 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 55 added.

The largest buyer was Armistice Capital, adding an estimated $23.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $30.1M sold.

  • 127 institutional investors held Treace Medical Concepts (TMCI) as of Q2 2024, down from 132 in Q1 2024.
  • Funds reported $264M of Treace Medical Concepts stock for Q2 2024, down 51% quarter-over-quarter.
  • 37 funds opened new Treace Medical Concepts positions in Q2 2024 and 41 closed out, a net change of -4 holders.
  • The largest Treace Medical Concepts buyer in Q2 2024 was Armistice Capital, an estimated $23.9M added.
  • The largest Treace Medical Concepts seller in Q2 2024 was Perceptive Advisors, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2024.